Stocks
Biogen Inc.BIIB
NASDAQHealthcareBiotechnology$181.55-1.81%
A biotechnology firm focused on developing therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's. Investors monitor Biogen for its pipeline of innovative treatments and its role in the competitive CNS drug market.
Market Cap: $26.6B52W Range: $110.04 – $202.41
Congressional Interest in Biogen Inc. (BIIB)
18 members of Congress have disclosed 50 trades in Biogen Inc. (BIIB), a Healthcare company. The buy/sell breakdown shows 21 purchases versus 29 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
18
Buys
21
Sells
29
Who in Congress Is Trading BIIB?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-05-05 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2022-03-17 | Josh Gottheimer | sell | $1K – $15K |